Lyell Immunopharma (NASDAQ:LYEL) Announces Quarterly Earnings Results, Misses Estimates By $5.53 EPS

Lyell Immunopharma (NASDAQ:LYEL) issued its quarterly earnings results on Thursday. The company reported ($7.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.15) by ($5.53), FiscalAI reports. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.02 million. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%.

Lyell Immunopharma Stock Down 11.3%

LYEL stock traded down $2.79 during mid-day trading on Friday, hitting $21.98. The company had a trading volume of 38,281 shares, compared to its average volume of 103,783. The company has a 50-day moving average price of $24.29 and a 200 day moving average price of $21.40. Lyell Immunopharma has a 12-month low of $7.65 and a 12-month high of $45.00. The company has a market capitalization of $466.90 million, a price-to-earnings ratio of -0.96 and a beta of -0.14.

Insider Activity

In related news, insider Gary K. Lee sold 1,671 shares of the stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total transaction of $39,084.69. Following the completion of the transaction, the insider directly owned 16,938 shares of the company’s stock, valued at approximately $396,179.82. This represents a 8.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Stephen J. Hill sold 1,236 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total value of $28,910.04. Following the transaction, the chief operating officer owned 17,795 shares of the company’s stock, valued at $416,225.05. This represents a 6.49% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 11,310 shares of company stock worth $264,285 over the last 90 days. Corporate insiders own 22.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. ExodusPoint Capital Management LP purchased a new position in shares of Lyell Immunopharma in the fourth quarter valued at $262,000. Marshall Wace LLP bought a new position in Lyell Immunopharma during the second quarter valued at $94,000. Jane Street Group LLC bought a new position in Lyell Immunopharma during the fourth quarter valued at $382,000. Barclays PLC grew its stake in shares of Lyell Immunopharma by 1,239.5% in the 4th quarter. Barclays PLC now owns 15,967 shares of the company’s stock worth $491,000 after buying an additional 14,775 shares in the last quarter. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Lyell Immunopharma in the 2nd quarter worth $159,000. 66.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on LYEL. Citizens Jmp initiated coverage on Lyell Immunopharma in a research note on Monday. They issued a “market outperform” rating and a $34.00 price objective for the company. HC Wainwright raised Lyell Immunopharma from a “neutral” rating to a “buy” rating and lifted their target price for the company from $20.00 to $45.00 in a research note on Tuesday, December 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $39.50.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.